Philips shareholders approve all proposals at the AGM 2026
Rhea-AI Summary
Royal Philips (NYSE: PHG) reported that shareholders approved all proposals at the Annual General Meeting on May 8, 2026. Resolutions included the appointment of John DeFord to the Supervisory Board, re-appointments of three supervisory members, and re-appointment of Roy Jakobs as President/CEO and Chairman.
Shareholders also discharged the Board of Management and Supervisory Board. Philips referenced its Annual Report 2025 for financial statements and provided links for dividend and board composition details.
Positive
- Shareholders approved all AGM proposals on May 8, 2026
- Appointment of John DeFord to Supervisory Board effective May 8, 2026
- Re-appointment of Roy Jakobs as President/CEO and Chairman effective May 8, 2026
- Re-appointments of Paul Stoffels, Herna Verhagen, and Sanjay Poonen
Negative
- Departure of Marc Harrison as Supervisory Board member after eight years
Key Figures
Market Reality Check
Peers on Argus
PHG slipped 0.26% while close peers were mixed: STE -0.4%, ZBH roughly flat, SNN slightly down, but DXCM +0.91% and PODD up 4.77%, pointing to stock-specific factors rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 results update | Positive | +3.0% | Strong Q1 order intake, comparable sales growth and margin expansion. |
| Apr 23 | Product launch | Positive | -2.2% | Launch of Bridge Plus Occlusion Balloon for managing rare SVC tears. |
| Apr 22 | Regulatory clearance | Positive | -0.8% | FDA 510(k) clearance for Rembra CT/RT platform expanding CT imaging access. |
| Apr 16 | Regulatory clearance | Positive | -1.6% | FDA 510(k) clearance for AI-powered Philips Spectral CT Verida system. |
| Apr 02 | Management/board role | Positive | -0.7% | Philips CMO appointed to MDIC board, linking to regulatory science efforts. |
Recent Philips headlines have mostly been positive, yet four of the last five news events were followed by share price declines within 24 hours.
Over the last several weeks, Philips has reported a series of operational and product milestones. On May 6, 2026, it highlighted strong Q1 order intake, comparable sales growth and margin expansion, which saw shares rise about 3%. However, FDA 510(k) clearances for the Rembra platform and Verida spectral CT, along with a new Bridge Plus Occlusion Balloon launch, all saw modest negative next-day reactions. Today’s AGM 2026 approvals reinforce management continuity and governance stability against this backdrop of largely positive but sometimes sold-into news.
Market Pulse Summary
This announcement confirms that Philips’ shareholders approved all AGM 2026 proposals, including the re-appointment of CEO Roy Jakobs and several Supervisory Board members, supporting strategic and leadership continuity. Ahead of the news, the stock traded at 27.16, below the 200-day MA of 28.09 and about 18.77% beneath the 33.435 52-week high. Recent history shows multiple positive operational and regulatory updates with mixed price follow-through, so observers may focus on execution against the 2026 outlook and subsequent operational milestones.
Key Terms
supervisory board financial
board of management financial
dividend financial
AI-generated analysis. Not financial advice.
May 8, 2026
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2026, including:
- Appointment of John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.
- Re-appointment of Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board, with effect from May 8, 2026.
- Re-appointment of Roy Jakobs (Dutch/German, 1974) as President/CEO and Chairman and member of the Board of Management, with effect from May 8, 2026.
- Discharge of the members of the Board of Management, and of the members of the Supervisory Board.
Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board and the Board of Management, we welcome John DeFord to the Supervisory Board. He brings extensive global MedTech experience and deep expertise across innovation, interventional domains, and regulatory and quality environments. We also sincerely thank Marc Harrison, who's second term ended at the end of the AGM, for his valued guidance and contributions over the past eight years. The re-appointments of Paul Stoffels, Herna Verhagen and Sanjay Poonen provide a strong combination of expertise and important continuity to support Philips as it advances its next strategic phase.”
Mr Sijbesma added: “We congratulate Roy Jakobs on his re-appointment as President/CEO and Chairman of the Board of Management. We have full confidence in his leadership to successfully lead Philips through its next phase as the company continues to strengthen execution, innovation and performance, and advance its strategic priorities.”
Roy Jakobs, CEO of Royal Philips, said: “I appreciate the continued trust and support of our shareholders and Supervisory Board. I would like to thank John DeFord for joining. Together with other Supervisory Board members, he brings valuable expertise to support management with strong oversight and guidance. I look forward to our continued close collaboration and am excited to deliver sustainable value for Philips and all its stakeholders as we drive profitable growth.”
Further details about the dividend can be found via this link, and additional information on the composition of the Board of Management, the Executive Committee and the Supervisory Board can be found here. Philips’ 2025 financial statements are included in its Annual Report 2025 that was published on February 19, 2026.
A full overview of the resolutions taken and more information about Philips’ AGM 2026 is available via this link.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 614869261
E-mail: Michael.Fuchs@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Roy Jakobs is re-appointed as Philips President/CEO and Chairman and member of the Board of Management
- Philips AGM 2026
